אמביאן סי.אר  6.25 מג ישראל - עברית - Ministry of Health

אמביאן סי.אר 6.25 מג

sanofi israel ltd - zolpidem tartrate - טבליות עם שחרור נרחב - zolpidem tartrate 6.25 mg - zolpidem - zolpidem - for the treatment of insomnia, characterized by difficulties with sleep onset and/or sleep maintenance (as measured by wake time after sleep onset).

אמביאן סי.אר 12.5 מג ישראל - עברית - Ministry of Health

אמביאן סי.אר 12.5 מג

sanofi israel ltd - zolpidem tartrate - טבליות עם שחרור נרחב - zolpidem tartrate 12.5 mg - zolpidem - zolpidem - for the treatment of insomnia, characterized by difficulties with sleep onset and/or sleep maintenance (as measured by wake time after sleep onset).

סטילנוקס 10 מג טבליות ישראל - עברית - Ministry of Health

סטילנוקס 10 מג טבליות

sanofi israel ltd - zolpidem tartrate - טבליות מצופות פילם - zolpidem tartrate 10 mg - zolpidem - zolpidem - indications are limited to treatment of severe sleep disorders in the following cases: - occasional insomnia - transient insomnia.

זודורם 5 ישראל - עברית - Ministry of Health

זודורם 5

unipharm ltd, israel - zolpidem tartrate - טבליה - zolpidem tartrate 5 mg - zolpidem

זודורם 10 ישראל - עברית - Ministry of Health

זודורם 10

unipharm ltd, israel - zolpidem tartrate - טבליות מצופות - zolpidem tartrate 10 mg - zolpidem

סלנייטו 1 מג ישראל - עברית - Ministry of Health

סלנייטו 1 מג

neurim pharmaceuticals (1991) ltd, israel - melatonin - טבליות בשחרור ממושך - melatonin 1 mg - melatonin

סלנייטו 5 מג ישראל - עברית - Ministry of Health

סלנייטו 5 מג

neurim pharmaceuticals (1991) ltd, israel - melatonin - טבליות בשחרור ממושך - melatonin 5 mg - melatonin

סנדוסטטין   0.1 מגמל ישראל - עברית - Ministry of Health

סנדוסטטין 0.1 מגמל

novartis israel ltd - octreotide - תמיסה להזרקה\אינפוזיה - octreotide 0.1 mg/ml - octreotide - octreotide - prevention of complications following pancreatic surgery. symptomatic control and reduction of gh and igf-1plasma levels in patients with acromegaly who are inadequately controlled by surgery or radiotherapy. sandostatin treatment is also indicated for acromegalic patients unfit or unwilling to undergo surgery or in the interim period until radiotherapy becomes fully effective. relief of symptoms associated with functional gastroenteropancreatic endocrine tumours: - carcinoid tumours with features of the carcinoid syndrome - vipomas - glucagonomas - gastrinomas / zollinger-ellison syndrome usually in conjunction with proton pump inhibitors or h2- antagonist therapy - insulinomas for pre-operative control of hypoglycaemia and for maintenance therapy - grfomas. sandostatin is not an antitumour therapy and is not curative in these patients.emergency management of bleeding gastro-oesophageal varices secondary to cirrhosis in combination with specific therapy such as endoscopic sclerotherapy.

סנדוסטטין   0.05 מגמל ישראל - עברית - Ministry of Health

סנדוסטטין 0.05 מגמל

novartis israel ltd - octreotide - תמיסה להזרקה\אינפוזיה - octreotide 0.05 mg/ml - octreotide - octreotide - prevention of complications following pancreatic surgery. symptomatic control and reduction of gh and igf-1plasma levels in patients with acromegaly who are inadequately controlled by surgery or radiotherapy. sandostatin treatment is also indicated for acromegalic patients unfit or unwilling to undergo surgery or in the interim period until radiotherapy becomes fully effective. relief of symptoms associated with functional gastroenteropancreatic endocrine tumours: - carcinoid tumours with features of the carcinoid syndrome - vipomas - glucagonomas - gastrinomas / zollinger-ellison syndrome usually in conjunction with proton pump inhibitors or h2- antagonist therapy - insulinomas for pre-operative control of hypoglycaemia and for maintenance therapy - grfomas. sandostatin is not an antitumour therapy and is not curative in these patients.emergency management of bleeding gastro-oesophageal varices secondary to cirrhosis in combination with specific therapy such as endoscopic sclerotherapy.

סנדוסטטין 0.5 מגמל ישראל - עברית - Ministry of Health

סנדוסטטין 0.5 מגמל

novartis israel ltd - octreotide - תמיסה להזרקה\אינפוזיה - octreotide 0.5 mg/ml - octreotide - octreotide - prevention of complications following pancreatic surgery. symptomatic control and reduction of gh and igf-1plasma levels in patients with acromegaly who are inadequately controlled by surgery or radiotherapy. sandostatin treatment is also indicated for acromegalic patients unfit or unwilling to undergo surgery or in the interim period until radiotherapy becomes fully effective. relief of symptoms associated with functional gastroenteropancreatic endocrine tumours: carcinoid tumours with features of the carcinoid syndrome. vipomas . glucagonomas . gastrinomas / zollinger-ellison syndrome usually in conjunction with proton pump inhibitors or h2- antagonist therapy . insulinomas for pre-operative control of hypoglycaemia and for maintenance therapy . grfomas. sandostatin is not an antitumour therapy and is not curative in these patients.emergency management of bleeding gastro-oesophageal varices secondary to cirrhosis in combination with specific therapy such as endoscopic sclerotherapy.